Cisplatin News and Research

RSS

Study identifies several therapeutically effective drugs for bladder cancer

Hundreds of chemical compounds were screened on cell cultures representing different stages and subtypes of bladder cancer and several promising agents with inhibitory (growth-inhibiting) effects were identified.

11 Apr 2022

Adding immunotherapy to chemotherapy before surgery improves outcomes for NSCLC patients

Adding the immunotherapy drug nivolumab to chemotherapy before surgery (neoadjuvant) for patients with operable non-small cell lung cancer (NSCLC) — the leading cause of cancer deaths worldwide — reduced the risk of recurrence of the cancer or death by more than one-third, according to results from the phase III CheckMate-816 trial.

11 Apr 2022

Sodium thiosulfate shows no benefits for reducing heart damage following a heart attack

Sodium thiosulfate showed no benefits for reducing injury to damaged areas of heart muscle following a heart attack, in a study presented at the American College of Cardiology's 71st Annual Scientific Session.

5 Apr 2022

Novel drug combination can boost chemoimmunotherapy response in bladder cancer patients

Adding an anti-inflammatory medication to immunotherapy and standard chemotherapy drugs may provide long-term suppression of aggressive bladder tumor growth, according to a proof-of-concept study led by Cedars-Sinai Cancer investigators.

28 Mar 2022

How malaria drugs could play a part in treating chemotherapy-resistant head and neck cancers

In this interview, we speak to Kirill Kiselyov, Ph.D, and Umamaheswar Duvvuri, M.D, Ph.D, from the University of Pittsburgh, about their latest research into hydroxychloroquine, a drug widely used to prevent and treat malaria, as a potential treatment for head and neck cancers.

28 Mar 2022

Study: Ketogenic diet helps kill pancreatic cancer cells when combined with a triple-drug therapy

The findings of a new study suggest that a ketogenic diet - which is low in carbohydrates and protein, but high in fat - helps to kill pancreatic cancer cells when combined with a triple-drug therapy developed by the Translational Genomics Research Institute (TGen), an affiliate of City of Hope.

22 Mar 2022

Malaria drug could help treat chemotherapy-resistant head and neck cancers

A new study suggests that the malaria drug hydroxychloroquine inhibits pathways that drive resistance to the chemotherapy agent cisplatin in head and neck cancers and restores tumor-killing effects of cisplatin in animal models.

14 Mar 2022

Biomarker could predict pathologic response to chemotherapy among bladder cancer patients

Long-term survival data from the first prospective, randomized biomarker validation trial in patients with muscle-invasive bladder cancer being treated with cisplatin-based chemotherapy before surgery will be reported at the 2022 Genitourinary Cancers Symposium of the American Society of Clinical Oncology (GU ASCO) on February 18, 2022.

15 Feb 2022

New drug effective in patients with muscle-invasive bladder cancer ineligible for cisplatin chemotherapy

Findings from a new study led by Yale Cancer Center researchers show enfortumab vedotin is effective in patients with muscle-invasive bladder cancer (MIBC) not eligible for cisplatin chemotherapy.

15 Feb 2022

New multiple-shot electroporation device could enable low-cost, effective cancer drug delivery

Researchers from the Singapore University of Technology and Design (SUTD) have developed a microsize-gap multiple-shot electroporation (M2E) device that could improve the effectiveness of delivering cancer drugs at a lower cost, globally.

12 Feb 2022

Ketogenic diet could enhance the efficacy of chemotherapy for pancreatic cancer, study shows

A Ludwig Cancer Research preclinical study has demonstrated that a common weight-loss diet could enhance the efficacy of chemotherapy for pancreatic cancer.

12 Feb 2022

30-year-old cancer drug could get another shot, study says

A study by Virginia Commonwealth University Massey Cancer Center researchers published in today's print edition of Molecular Cancer Therapeutics shows that triplatin is effective against triple negative breast cancer, which is the most aggressive form of breast cancer and has few targeted therapies.

9 Feb 2022

Study points to a new, effective treatment option for patients with mesothelioma

Combining the immunotherapy agent durvalumab with the chemotherapy agents pemetrexed and cisplatin or carboplatin may provide a new treatment option for patients who have inoperable pleural mesothelioma, a cancer of the tissues lining the lungs, according to a phase II clinical trial led by researchers at the Johns Hopkins Kimmel Cancer Center and the Bloomberg~Kimmel Institute for Cancer Immunotherapy.

8 Nov 2021

Researchers compare transcriptomic and cytokine responses of colorectal cancer cells

Oncotarget published "Pan-drug and drug-specific mechanisms of 5-FU, irinotecan (CPT-11), oxaliplatin, and cisplatin identified by comparison of transcriptomic and cytokine responses of colorectal cancer cells" which reported that there was an increase in IL-8 by oxaliplatin and increase in ferritin by cisplatin which may contribute to cancer cell survival.

29 Sep 2021

Neoadjuvant CPA followed by surgical resection and maintenance atezolizumab meets safety criteria

Neoadjuvant cisplatin and pemetrexed plus atezolizumab followed by surgical resection and maintenance atezolizumab met safety criteria, according to research presented today in OA13: Topics in Pleural Mesothelioma at the IASLC 2021 World Conference on Lung Cancer.

12 Sep 2021

Younger children more vulnerable to chemotherapy-related hearing loss, study finds

A chemotherapy drug known to cause hearing loss in children is more likely to do so the earlier in life children receive it, new UBC research has found.

7 Sep 2021

Chemotherapy drug can cause permanent hearing loss in young children with cancer

The chemotherapy drug cisplatin is an effective cancer treatment for many children with cancer, but unfortunately it can cause permanent hearing loss.

7 Sep 2021

Adding berzosertib to standard treatment for metastatic urothelial cancer does not extend patient survival

A Phase 2 trial led by City of Hope, a world-renowned research and treatment center for cancer and diabetes, suggests that adding the novel ataxia telangiectasia and Rad3-related (ATR) inhibitor drug berzosertib to standard-of-care chemotherapy for patients with metastatic urothelial cancer does not extend progression-free survival.

27 Aug 2021

Removal of race from kidney function estimates may negatively impact care for Black cancer patients

An accurate assessment of a patient's kidney function is critical for determining eligibility for anticancer treatments.

14 Aug 2021

New research offers hope to increase efficacy of immunotherapy for lung cancer

Lung cancer is the leading cause of cancer-related death. Current treatments employ immunotherapy, often in combination with chemotherapy, but benefits to patients remain slight.

11 Aug 2021